[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338690-105":59,"doc-detail-338690-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","prospective-evaluation-of-pi-radsv21-using-multiparametric-and-biparametric-mri-for-detecting-clinically-significant-prostate-cancer-based-on-mrius-fusion-guided-biopsy","Prospective evaluation of PI-RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion-guided biopsy","","Purpose To evaluate cancer detection rates across each Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) category using multiparametric MRI (mpMRI) and biparametric MRI (bpMRI) based on MRI/ultrasound fusion biopsy. Materials and methods Prospective participants underwent PI-RADSv2.1 interpretation on mpMRI or bpMRI, followed by MRI/US-fusion biopsy (Aug 2022–Dec 2023). Lesion-based csPCa detection rates by category and association with ISUP grade groups were assessed; diagnostic performance of PI-RADSv2.1 for csPCa was evaluated and mpMRI vs bpMRI compared using PI-RADSv2.1 category cut-offs.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prospective-evaluation-of-pi-radsv21-using-multiparametric-and-biparametric-mri-for-detecting-clinically-significant-prostate-cancer-based-on-mrius-fusion-guided-biopsy/338690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prospective-evaluation-of-pi-radsv21-using-multiparametric-and-biparametric-mri-for-detecting-clinically-significant-prostate-cancer-based-on-mrius-fusion-guided-biopsy/338690.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How was PI-RADSv2.1 evaluated in the prospective study?","Question",{"text":113,"@type":114},"Participants underwent mpMRI or bpMRI with PI-RADSv2.1 interpretation, followed by MRI/US-fusion biopsy. Lesion-based csPCa detection rates were calculated for each PI-RADSv2.1 category.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What relationship did PI-RADSv2.1 categories show with clinically significant prostate cancer?",{"text":118,"@type":114},"PI-RADSv2.1 categories were significantly positively associated with csPCa detection rates for both mpMRI and bpMRI, with positive association and reported p-values.",{"name":120,"@type":111,"acceptedAnswer":121},"Did mpMRI and bpMRI differ in detecting csPCa using PI-RADSv2.1 cut-offs?",{"text":122,"@type":114},"No significant differences were found between mpMRI and bpMRI for PI-RADS v2.1 positive versus negative lesions, and bpMRI performance was compatible with mpMRI using PI-RADSv2.1 category cut-offs ≥3 or ≥4.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338690,1790034169,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Japanese Journal of Radiology (2025) 43:472–482 [https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1604-024-01675-4  \nProspective evaluation of PI‑RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion‑guided biopsy  \nNaohiro Yamaya1,2 · Koichiro Kimura1 · Ryota Ichikawa1,3 · Masaaki Kawanishi1,4 · Yusuke Kawasaki1,5 · Subaru Higuchi1,6 · Kenichi Fukui1 · Junichi Tsuchiya1 · Masaki Kobayashi7 · Soichiro Yoshida7 · Yasuhisa Fujii7 · Ukihide Tateishi1  \nReceived: 9 July 2024 / Accepted: 1 October 2024 / Published online: 16 October 2024 © The Author(s) 2024  \nAbstract  \nPurpose To evaluate the cancer detection rates for each category of Prostate Imaging-Reporting and Data System version 2.1 (PI-RADSv2.1) using multiparametric magnetic resonance imaging (mpMRI) and biparametric MRI (bpMRI) based on MRI/ultrasound (US)-fusion biopsy.  \nMaterials and methods This prospective study included participants who underwent mpMRI or bpMRI with a PI-RADSv2.1 interpretation and subsequently received MRI/US-fusion biopsy between August 2022 and December 2023. The lesionbased detection rates of clinically significant prostate cancer (csPCa) in each PI-RADSv2.1 category and the correlation between PI-RADSv2.1 categories and International Society of Urological Pathology (ISUP) grade groups were analyzed. The diagnostic performance of PI-RADSv2.1 in predicting csPCa was evaluated, and diagnostic performance of mpMRI and bpMRI was compared using cut-offs, with PI-RADSv2.1 categories ≥ 3 or ≥ 4 defined as positive.  \nResults A total of 247 lesions from 216 participants were included in this study. A total of 157 patients underwent mpMRI and the remaining 59 underwent bpMRI. The csPCa detection rates for each PI-RADSv2.1 category of mpMRI and bpMRI were as follows: category 1, 0%(0/11); 2, 13%(3/23); 3, 16%(5/31); 4, 60%(43/72); 5, 65%(26/40), in mpMRI; category 1, 0%(0/4); 2, 33%(1/3); 3, 25%(3/12); 4, 61%(19/31); 5, 75%(15/20) in bpMRI. PI-RADSv2.1 categories were significantly positively associated with csPCa detection rates in both mpMRI and bpMRI (p \u003C 0.0001 and p = 0.00048, respectively) . PI-RADSv2.1 categories correlated with ISUP grade groups for mpMRI and bpMRI (p \u003C 0.0001 for both) . There were no significant differences in the detection rates between mpMRI and bpMRI for PI-RADS v2.1 positive and negative lesions. Conclusion PI-RADSv2.1 using mpMRI and bpMRI could stratify the risk of csPCa, and the csPCa detection rate of bpMRI was compatible with that of mpMRI using cut-offs of PI-RADSv2.1 categories ≥ 3 or ≥ 4.  \nKeywords Prostate Cancer · Prostate Imaging-Reporting and Data System version 2.1 · Multiparametric MRI · Biparametric MRI · MRI/US-fusion biopsy  \n* Koichiro Kimura [kmrdrnm@tmd.ac.jp](kmrdrnm@tmd.ac.jp)  \n1 Department of Diagnostic Radiology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113–8510, Japan  \n2 Department of Radiology, Kameda Medical Center, Chiba, Japan  \n3 Department of Diagnostic Imaging, Cancer Institute Hospital of JFCR, Tokyo, Japan  \n4 Department of Diagnostic Radiology, JA Toride Medical Center, Ibaraki, Japan  \n5 Department of Radiology, Asahi General Hospital, Chiba, Japan  \n6 Department of Radiology, Soka City Hospital, Saitama, Japan  \n7 Department of Urology, Tokyo Medical and Dental University, Tokyo, Japan  \nIntroduction  \nProstate cancer (PCa) is the second most common cancer in men and fourth most common malignancy considering both sexes. Most PCa cases in the United States grow slowly and showed a 5-year relative survival rate of 97%. Despite a good prognosis, due to the large number of patients with PCa, the number of deaths has reached 396,792, with PCa being the fifth leading cause of cancer related mortality among men in 2022 [1]. The American Cancer Society recommends that asymptomatic males, who are expected to have a 10-year life expectancy, be offered the opportunity to make an informe","cbCaie8bhP1pJE7T","https://ap.wps.com/l/cbCaie8bhP1pJE7T","pdf",1301397,11,"English","# Introduction\n# Materials and methods\n# Results\n# Conclusion","[{\"question\":\"How was PI-RADSv2.1 evaluated in the prospective study?\",\"answer\":\"Participants underwent mpMRI or bpMRI with PI-RADSv2.1 interpretation, followed by MRI/US-fusion biopsy. Lesion-based csPCa detection rates were calculated for each PI-RADSv2.1 category.\"},{\"question\":\"What relationship did PI-RADSv2.1 categories show with clinically significant prostate cancer?\",\"answer\":\"PI-RADSv2.1 categories were significantly positively associated with csPCa detection rates for both mpMRI and bpMRI, with positive association and reported p-values.\"},{\"question\":\"Did mpMRI and bpMRI differ in detecting csPCa using PI-RADSv2.1 cut-offs?\",\"answer\":\"No significant differences were found between mpMRI and bpMRI for PI-RADS v2.1 positive versus negative lesions, and bpMRI performance was compatible with mpMRI using PI-RADSv2.1 category cut-offs ≥3 or ≥4.\"}]","Prospective evaluation of PI-RADSv2.1 using multiparametric and biparametric MRI for detecting clinically significant prostate cancer based on MRI/US fusion-guided biopsy | PDF",1790025108,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad84c06ff4dff75c25ed62b903dc61b6.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e12ad5312001cdd669ff08b73bcef158.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98f6cb216d8180e98fdb35cf7bf396d9.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a38f9f4cfb6514043d021b5b0bd4f45.webp",980,1301]